- Home
- TWST
as 09-06-2024 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.7B | IPO Year: | 2018 |
| Target Price: | $48.22 | AVG Volume (30 days): | 724.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.42 - $60.90 | Next Earning Date: | 08-02-2024 |
| Revenue: | $295,210,000 | Revenue Growth: | 25.37% |
| Revenue Growth (this year): | 29.39% | Revenue Growth (next year): | 20.02% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Aug 23 '24 | Sell | $43.14 | 813 | $35,074.45 | 38,964 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Aug 5 '24 | Sell | $39.93 | 5,139 | $205,179.71 | 499,593 | |
| Cho Dennis | TWST | See Remarks | Aug 5 '24 | Sell | $39.93 | 709 | $28,307.53 | 78,996 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Aug 5 '24 | Sell | $39.93 | 168 | $6,707.57 | 38,964 | |
| Finn Patrick John | TWST | President and COO | Aug 5 '24 | Sell | $39.93 | 2,885 | $115,186.51 | 168,327 | |
| Finn Patrick John | TWST | President and COO | Jul 23 '24 | Sell | $56.63 | 2,207 | $124,971.38 | 168,327 | |
| Laponis Adam | TWST | Chief Financial Officer | Jul 9 '24 | Sell | $48.91 | 842 | $41,184.75 | 73,602 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Jul 2 '24 | Sell | $48.00 | 1,114 | $53,474.23 | 499,593 | |
| Cho Dennis | TWST | See Remarks | Jul 2 '24 | Sell | $48.00 | 126 | $6,048.25 | 78,996 | |
| Finn Patrick John | TWST | President and COO | Jul 2 '24 | Sell | $48.00 | 476 | $22,848.95 | 168,327 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Business Wire
13 days ago
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
Business Wire
a month ago
Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb
Business Wire
a month ago
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
MT Newswires
a month ago
Twist Bioscience Begins New Partnership to Create Transaminase Screening Kit for Drug Makers; Shares Rising
MT Newswires
a month ago
JPMorgan Raises Twist Bioscience Price Target to $35 From $28, Maintains Underweight Rating
Business Wire
a month ago
Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis
Simply Wall St.
a month ago
Twist Bioscience Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
a month ago
Sector Update: Health Care Stocks Decline Premarket Friday
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.